Press Releases

Havn Life Sciences announces closing of C$11.5 million Bought Deal Financing

Havn Life Sciences announces closing of C$11.5 million Bought Deal Financing

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP) (the “Company” or “Havn Life”) is pleased to announce that, further to its news release dated December 15, 2020, the Company has completed its previously announced bought deal …

Havn Life Sciences announces closing of C$11.5 million Bought Deal Financing Read More »

Havn Life Sciences authorized product listing with Canadian health & wellness retailer, Nesters Market

Havn Life Sciences and Nesters Market, a leading Canadian retailer of Natural Health and Wellness Products, announce an authorized products listing

Nesters Market retail chain, will list and promote the full range of Havn Life’s natural health supplements across its stores in British Columbia in Q1 2021. Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP) (the “Company” or “Havn Life”), a biotechnology company pursuing standardized extraction of psychoactive compounds, the development …

Havn Life Sciences and Nesters Market, a leading Canadian retailer of Natural Health and Wellness Products, announce an authorized products listing Read More »

Havn Life Sciences Files Preliminary Prospectus in Connection with Bought Deal Equity Financing

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES December 18, 2020 – Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP) (the “Company” or “Havn Life”) is pleased to announce, further to its previously announced offering (the “Offering”) on December 15, 2020, that it has …

Havn Life Sciences Files Preliminary Prospectus in Connection with Bought Deal Equity Financing Read More »

Havn Life provides update on retail strategy and product development

Havn Life Sciences provides update on retail strategy and product development

Havn Retail is on track for its Q1 2021 launch of its initial line of natural health supplements. Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP) (the “Company” or “Havn Life”), a biotechnology company pursuing standardized extraction of psychoactive compounds, the development of a full range of natural healthcare products, …

Havn Life Sciences provides update on retail strategy and product development Read More »

CBDV Exemption 56 Havn Life

Havn Life Sciences hits major milestone with research partner, Complex Biotech Discovery Ventures

Havn Research signs contract with CBDV, located at The University of British Columbia’s Vancouver campus, to begin Health Canada approved research to analyze psilocybin under Havn Life’s Section 56 exemption. The results of the analysis will allow Havn Life to begin the development of a library of psilocybin compounds. Vancouver, BC – Havn Life Sciences …

Havn Life Sciences hits major milestone with research partner, Complex Biotech Discovery Ventures Read More »

Havn Life Sciences announces increase in Bought Deal Financing to $10 Million

Havn Life Sciences announces increase in Bought Deal Financing to $10 Million

Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP) (the “Company” or “Havn Life”) is pleased to announce that it has entered into an amended agreement with Eight Capital, pursuant to which Eight Capital has now agreed to buy, on a bought deal basis, 9,346,000 units (“Units”) at a price of …

Havn Life Sciences announces increase in Bought Deal Financing to $10 Million Read More »

Havn Life Sciences announces $5 million Bought Deal Financing

Havn Life Sciences announces $5 million Bought Deal Financing

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP) (the “Company” or “Havn Life”) is pleased to announce that it has entered into an agreement with Eight Capital, pursuant to which Eight Capital has agreed to buy, …

Havn Life Sciences announces $5 million Bought Deal Financing Read More »

Havn Life Sciences undertakes one of the first preclinical studies on psilocybin and the immune system

This is one of the first studies to examine how psilocybin affects the immune system and is a required step to file an application with the Food and Drug Administration (FDA), for a Phase 1 clinical study in humans. Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP) (the “Company” or …

Havn Life Sciences undertakes one of the first preclinical studies on psilocybin and the immune system Read More »

Havn Life Psychedelics Heroic Hearts

Havn Life Sciences to supply psychedelic compounds to clinical studies focused on veterans and PTSD

Havn Life will collaborate on future clinical studies in the U.S. and Canada with Heroic Hearts to investigate effects of low-dosage psychoactive compounds on veterans the post-traumatic stress disorder (PTSD). Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP) (the “Company” or “Havn Life”), a Canadian biotechnology company pursuing standardized extraction …

Havn Life Sciences to supply psychedelic compounds to clinical studies focused on veterans and PTSD Read More »

Havn Life Sciences announces Investor Relations Marketing Campaigns

Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP) (the “Company” or “Havn Life”), is pleased to announce that it has entered into investor relations agreements with Media Relations Publishing (“MRP”) and Midam Ventures, LLC (“Midam”), respectively, pursuant to which, in exchange for payment by the Company of CAD$500,000 to each …

Havn Life Sciences announces Investor Relations Marketing Campaigns Read More »

Scroll to Top